社区

New York, NY – March 9, 2026 – Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful strategic showcase at the 2026 North American Society for Interventional Thyroidology (NASIT) in Portland, Oregon. This engagement advances the Company’s goal to expand patient access to advanced, minimally invasive treatment options.

纽约州纽约市 – 2026年3月9日 – 微创微波消融（MWA）技术的市场领导者百德医疗投资控股有限公司（纳斯达克股票代码：BDMD）（以下简称“百德医疗”或“公司”）今日宣布，其成功在俄勒冈州波特兰市举办的2026年北美介入甲状腺病学会（NASIT）上进行了战略展示。此次参会推进了公司旨在让更多患者获得先进微创治疗方案的目标。

NASIT 2026

Specialists exploring Baird Medical’s MWA technology

Baird Medical’s proprietary MWA platforms garnered significant interest during the event's thermal ablation workshop and at the Company's dedicated exhibit. Leadership facilitated targeted discussions with established Key Opinion Leaders (KOLs) and emerging physicians, exchanging critical insights on the clinical applications of MWA technology. Through these interactions, the Company showcased how integrating precision, non-surgical interventions into modern treatment paradigms can elevate the standard of patient care.

百德医疗专有的微波消融平台在该活动的热消融研讨会及公司专属展台上引起了广泛关注。公司领导层与资深关键意见领袖（KOL）及新锐医师进行了针对性探讨，就微波消融技术的临床应用交换了重要见解。通过这些交流互动，公司充分展示了将精准、非手术干预手段整合至现代治疗模式中，将有效提升患者的护理标准。

"Our robust presence at NASIT directly advances our mission to elevate the standard of care across the United States," stated Mark Saxton, U.S. CEO of Baird Medical. "By connecting with established pioneers and new specialists at the forefront of thermal ablation, we are accelerating the adoption of precision therapies and empowering providers to deliver superior, minimally invasive outcomes.”

百德医疗美国首席执行官Mark Saxton表示：“我们在NASIT上的强劲表现，推进了我们在全美提升医疗护理标准的使命。通过与处于热消融前沿的资深先驱和新晋专家建立联系，我们正在加速精准疗法的普及，并赋能医疗服务提供者，以实现卓越的微创治疗效果。”

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical’s solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company’s minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact: Eric Huang, PR Liaison

Baird Medical Investment Holdings Ltd.

Phone: +1 (888) 508-6228

Email: ir@bairdmed.com